医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q2 and Half Year FY13 Results on October 30, 2012

2012年10月10日 PM10:11
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half Year ended September 30, 2012 on Tuesday, October 30, 2012 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com

Summary of Events

Event   Date and Time (IST)   Medium
Release of financial results   Oct 30th, after the Board Meeting  

Email, Media, Company website, Business Wire

Earnings Call   Oct 30th, 6.30 PM IST / 9:00 AM EDT  

Hosted by the Company (Details below)

 

Webcast of Earnings Call   Oct 30th, 6.30 PM IST / 9.00 AM EDT through Nov 4th, 2012  

URL available on Company’s website, www.drreddys.com

 

Transcripts of the Earnings call   Will be available on the Company’s website  

URL available on Company’s website, www.drreddys.com

   

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance.

Conference Dial-In Numbers
Primary Number:   +91 22 3065 0136
Secondary Number:   +91 22 6629 0356
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:  

6000 1221
Available in – Ahmedabad, Bangalore, Chennai, Cochin, Delhi (NCR), Hyderabad, Kolkata, Lucknow

Accessible from all major carriers except BSNL/MTNL.

3940 3977
Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

Accessible from all carriers.

International Toll Free Number:   USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through Nov 4th, 2012. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

*EDT- Eastern Daylight Time

CONTACT

Dr. Reddy’s Laboratories
Investor Relations:
Kedar
Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak
Savla, +91 40 49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 9082034931
mkalawadia@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表